ABBOTT PARK, Ill., March 6, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has cleared its FreeStyle Libre 2 and FreeStyle Libre 3 integrated ...

Abbott has received CE Mark clearance for the second generation of its Freestyle Libre device, which will allow the company to make the device available to users in Europe. It will be rolled out ...

Following a major sales bump in the second quarter of 2019, Abbott Laboratories is planning to significantly ramp up manufacturing for its FreeStyle Libre continuous glucose monitoring system, the ...

Libre Assist 1 uses generative AI to predict how a food choice may affect a person's glucose levels. 2 It then offers actionable and personalized meal guidance 3 to support in-the-moment decisions.

Medical device giant Abbott announced on Sunday that it is recalling approximately 3 million glucose monitoring sensors after discovering they could give dangerously inaccurate low blood sugar ...

Diabetes remains a serious chronic disease worldwide, affecting approximately 589 million people 3 and often accompanied by cardiovascular complications. 4 People with Type 1 and Type 2 diabetes are 2 ...

WASHINGTON — Malfunctioning glucose sensors used by millions of people with diabetes have been tied to more than 700 serious injuries and seven deaths worldwide, according to new information released ...

Abbott is tapping the spirit of new beginnings for the New Year by unveiling a “gamechanger" feature within the company’s Libre app: Libre Assist. Timed to launch during this week’s CES 2026 ...